Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration–approved duration

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 6, 2017, Pages 586.e1-586.e6

  McNicholas, Colleen ^a   Swor, Erin ^a   Wan, Leping ^a   Peipert, Jeffrey F ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

effectiveness; Food and Drug Administration approved duration; implant; intrauterine device; prolonged use

Indexed keywords

ETONOGESTREL; LEVONORGESTREL; CONTRACEPTIVE AGENT; DESOGESTREL; DRUG IMPLANT;

ADULT; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG IMPLANT; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; OBESITY; OUTCOME ASSESSMENT; OVULATION; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNPLANNED PREGNANCY; ADOLESCENT; INTRAUTERINE CONTRACEPTIVE DEVICE; MIDDLE AGED; PREGNANCY; TIME FACTOR; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; BODY MASS INDEX; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; PREGNANCY; PREGNANCY, UNPLANNED; PROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 85019680215     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.01.036     Document Type: Article

References (10)

1. Daniels, K., Daugherty, J., Jones, J., Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS Data Brief(173), 2014, 1–8.
2. McNicholas, C., Maddipati, R., Zhao, Q., Swor, E., Peipert, J.F., Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the US Food and Drug Administration–approved duration. Obstet Gynecol 125 (2015), 599–604.
3. Sivin, I., Long-term use of copper intrauterine devices. Lancet, 336, 1990, 504.
4. Kiriwat, O., Patanayindee, A., Koetsawang, S., Korver, T., Bennink, H.J., A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 3 (1998), 85–91.
5. Wu, J.P., Pickle, S., Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception 89 (2014), 495–503.
6. Ali, M., Akin, A., Bahamondes, L., et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod 31 (2016), 2491–2498.
7. World Health Organization. Global database on body mass index. Available from: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed March 10, 2017.
8. Westhoff, C.L., Torgal, A.H., Mayeda, E.R., et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 207 (2012), 39.e1–39.e6.
9. Xu, X., Macaluso, M., Frost, J., Anderson, J.E., Curtis, K., Grosse, S.D., Characteristics of users of intrauterine devices and other reversible contraceptive methods in the United States. Fertil Steril 96 (2011), 1138–1144.
10. Mornar, S., Chan, L.N., Mistretta, S., Neustadt, A., Martins, S., Gilliam, M., Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol 207 (2012), 110.e1–110.e6.